T Nagar, Chennai, Tamil Nadu
GST No. 33AGQPV7819N1ZD
Product Price :Get Latest PriceProduct Details:
|Packaging Size||1.2 ml|
Celrixafor is the Generic version of Mozobil. On December 15, 2008, the U. S. Food and Drug Administration (FDA) approved plerixafor, solution for subcutaneous injection, (Mozobil™, Genzyme Corp.) for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).
Peripheral blood stem cell mobilization, which is important as a source of hematopoietic stem cells for transplantation, is usually performed using granulocyte colony-stimulating factor (G-CSF), but is ineffective in around 15 to 20% of patients. Combination of G-CSF with Celrixafor (Plerixafor) increases the percentage of persons that respond to the therapy and produce enough stem cells for transplantation.
Explore More Products